このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

化学療法誘発性末梢神経障害の治療としてのニューロモデュレーション

2026年11月16日 更新者:M.D. Anderson Cancer Center

The goal of this clinical research study is to learn if using a type of non-invasive therapy called neurofeedback training can help teach patients with peripheral neuropathy how to change their own brain waves to lower their perception of neuropathy and help improve their overall quality of life.

Neurofeedback training is a type of therapy that uses an electroencephalograph (EEG) and a computer software program to measure brain wave activity.

This is an investigational study. The equipment used for neurofeedback training is FDA approved and commercially available. Using neurofeedback equipment to teach patients ways to modify their own brain waves to lower the perception of symptoms and improve quality of life is considered investigational.

Up to 99 participants over the age of 18 will take part in this study. All will be enrolled at MD Anderson.

調査の概要

詳細な説明

Baseline Tests:

If you agree to take part in this study, you will have the following baseline tests:

  • You will complete 7 questionnaires about your symptoms, how you have been feeling, and your general quality of life. It should take about 20 minutes to complete.
  • Basic information about you (such as your age and education level) will also be collected.
  • You will have an EEG to measure the electrical activity of your brain. During the EEG, researchers will place a cap containing 19 electrodes on your scalp and 1 electrode on each earlobe. The electrodes will measure and record your brain wave activity, similar to the way a doctor listens to your heart beat from the surface of your skin. The EEG should take about 45 minutes to complete.

Study Groups:

After completing the baseline tests, you will be randomly assigned (as in the roll of a dice) to 1 of 3 study groups. This is done because no one knows if one study group is better, the same, or worse than the other group.

  • If you are assigned to Group 1, you will receive traditional neurofeedback training. Traditional neurofeedback training rewards you based on your own brain's activity.
  • If you are assigned to Group 2, you will receive sham neurofeedback training. Sham neurofeedback training does not use your own brainwaves. In sham neurofeedback, you will be training from the brainwaves of another person who does not have neuropathy. Sham neurofeedback is not designed to help train your brainwaves. It is designed to be compared with traditional neurofeedback to learn if traditional neurofeedback has any real effect. If you have any questions about how sham neurofeedback is designed to work, talk with the study doctor or study staff.
  • If you are assigned to Group 3, you will continue to receive standard care. You will not take part in the neurofeedback training, but you will take part in the follow-up visits (described below).

If you are assigned to Groups 1 or 2, you will not be told if you are receiving traditional neurofeedback training or sham training.

Neurofeedback Training (Groups 1 and 2):

You will have at least 2 neurofeedback training sessions each week for up to 10 weeks (20 training sessions total). The training sessions may take place on any 2 days of the week and may be up to 5 times a week, if you are interested in training more quickly. The study doctor will discuss the option of training faster with you.

Each neurofeedback training session should take about 1 hour to complete.

During each session, you will have an EEG while you sit quietly, relax, and watch a computer screen. The screen will be blank at first and then a series of pictures will appear. The pictures will change as your brainwaves change. You may also be shown pictures of flowers, bridges, mountains, and so on. You may be asked to play small games, for example a Pac-Man type game in which a small character moves around a maze. You will be able to choose to either view pictures or play a game.

When researchers see that your brain waves change in the way they are looking for, you will be "rewarded." When you are rewarded you will see a pretty picture on screen and you will hear a beep.

A neurotherapist will be present during each session to make sure you do not fall asleep and that you are relaxed during the procedure.

At each neurofeedback training session, you will also be asked to rate your neuropathic symptoms on a scale of 0-10 before you begin the neurofeedback training and again after the session is complete. This should only take a few minutes.

Length of Participation:

Your active participation on this study will be over after follow-up. If you are in Groups 2 or 3, you may be able to stay on study for an additional 4 months if you agree to Optional Procedure #1 (described below).

Follow-Up (All groups):

Within 1 week after your last neurofeedback training session and again about 1 month later:

  • You will fill out the same 7 questionnaires you completed at baseline.
  • You will have an EEG. If you are in Group 3, you will have this EEG about 1 week after Group 1 has completed their neurofeedback training.
  • After you have completed the assessment 1 month later, you will be told which group you were in and offered neurofeedback if you were in the sham group.

研究の種類

介入

入学 (実際)

91

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • University of Texas MD Anderson Cancer Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Patients must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
  3. Pain score >/= 4 on a 0-10 numeric pain scale and/or grade 3 neuropathic symptoms according to the National Cancer Institute's 4 point grading scale.
  4. Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician).
  5. Patients must report neuropathic pain for a minimum of 3 months.
  6. No plans to change pain medication regimen during the course of the study.
  7. Off active chemotherapy treatment for minimum of 6 months.
  8. Willing to come to MD Anderson for the therapy sessions; or willing to participate in the therapy sessions at their homes and live within a 45 minute drive of MDA main campus; or can participate in the therapy sessions from one of MDA's Regional Care Centers.
  9. Patients who are 18 years of age or above
  10. Patients who have a diagnosis of breast cancer.

Exclusion Criteria:

  1. Patients who are taking any antipsychotic medications.
  2. Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy.
  3. Patients who have ever been diagnosed with bipolar disorder or schizophrenia.
  4. Patients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapy.
  5. Patients who have a history of head injury or who have known seizure activity.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Neurofeedback Training

Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.

Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.

Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.

他の名前:
  • 脳波

Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.

他の名前:
  • 調査
  • アンケート

Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

他の名前:
  • 調査
偽コンパレータ:Sham Neurofeedback Training

Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.

Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.

Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.

他の名前:
  • 脳波

Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.

他の名前:
  • 調査
  • アンケート

Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

他の名前:
  • 調査
他の:Standard of Care

Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.

Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.

Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.

他の名前:
  • 脳波

Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

他の名前:
  • 調査

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Effects of Active, Deactivated, and No Neurofeedback (NF) on Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
時間枠:4 months

Pain Quality Assessment Scale (PQAS) used to evaluate responses in each group.

4 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Effects of Neurofeedback on the Cortical and Subcortical Regions of the Pain Matrix Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN)
時間枠:4 months

Changes in neuromodulation assessed using a quantitative EEG.

4 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jia Wu、M.D. Anderson Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2015年10月1日

一次修了 (推定)

2028年10月1日

研究の完了 (推定)

2028年10月1日

試験登録日

最初に提出

2015年10月7日

QC基準を満たした最初の提出物

2015年10月8日

最初の投稿 (推定)

2015年10月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2015-0399
  • 5K01AT008485-02 (米国 NIH グラント/契約)
  • NCI-2015-01923 (レジストリ識別子:NCI CTRP)
  • CCR-14-800 (その他の助成金/資金番号:Rising Tide Foundation)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する